211 related articles for article (PubMed ID: 27053681)
21. MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway.
Li M; Zheng R; Yuan FL
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5987-5993. PubMed ID: 30280781
[TBL] [Abstract][Full Text] [Related]
22. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
23. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
[TBL] [Abstract][Full Text] [Related]
24. Muscle-specific deletion of SOCS3 increases the early inflammatory response but does not affect regeneration after myotoxic injury.
Swiderski K; Thakur SS; Naim T; Trieu J; Chee A; Stapleton DI; Koopman R; Lynch GS
Skelet Muscle; 2016; 6():36. PubMed ID: 27800152
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of SOCS3 and its biological function in colorectal cancer.
Chu Q; Shen D; He L; Wang H; Liu C; Zhang W
Gene; 2017 Sep; 627():114-122. PubMed ID: 28603075
[TBL] [Abstract][Full Text] [Related]
26. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Chen T; Wang LH; Farrar WL
Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
[TBL] [Abstract][Full Text] [Related]
27. SOCS3 promotor hypermethylation and STAT3-NF-κB interaction downregulate SOCS3 expression in human coronary artery smooth muscle cells.
Dhar K; Rakesh K; Pankajakshan D; Agrawal DK
Am J Physiol Heart Circ Physiol; 2013 Mar; 304(6):H776-85. PubMed ID: 23335796
[TBL] [Abstract][Full Text] [Related]
28. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
29. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
Smith R; Liu M; Liby T; Bayani N; Bucher E; Chiotti K; Derrick D; Chauchereau A; Heiser L; Alumkal J; Feiler H; Carroll P; Korkola JE
Sci Rep; 2020 Dec; 10(1):21750. PubMed ID: 33303959
[TBL] [Abstract][Full Text] [Related]
30. SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.
Lahera A; López-Nieva P; Alarcón H; Marín-Rubio JL; Cobos-Fernández MÁ; Fernández-Navarro P; Fernández AF; Vela-Martín L; Sastre I; Ruiz-García S; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Br J Haematol; 2023 May; 201(4):718-724. PubMed ID: 36786170
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth.
Wolff DW; Xie Y; Deng C; Gatalica Z; Yang M; Wang B; Wang J; Lin MF; Abel PW; Tu Y
Int J Cancer; 2012 Apr; 130(7):1521-31. PubMed ID: 21500190
[TBL] [Abstract][Full Text] [Related]
32. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
[TBL] [Abstract][Full Text] [Related]
33. m
Wu R; Liu Y; Zhao Y; Bi Z; Yao Y; Liu Q; Wang F; Wang Y; Wang X
Cell Death Dis; 2019 Feb; 10(3):171. PubMed ID: 30787270
[TBL] [Abstract][Full Text] [Related]
34. Janus kinase/signal transducer and activator of transcription signaling pathway-related genes STAT3, SOCS3 and their role in thiram induced tibial dyschondroplasia chickens.
Chen SM; Jahejo AR; Nabi F; Ahmed S; Zhao JF; Yu J; Zhang CL; Ning GB; Zhang D; Raza SHA; Tian WX
Res Vet Sci; 2021 May; 136():25-31. PubMed ID: 33578291
[TBL] [Abstract][Full Text] [Related]
35. Protective effects of SOCS3 overexpression in high glucose‑induced lung epithelial cell injury through the JAK2/STAT3 pathway.
Duan WN; Xia ZY; Liu M; Sun Q; Lei SQ; Wu XJ; Meng QT; Leng Y
Mol Med Rep; 2017 Sep; 16(3):2668-2674. PubMed ID: 28713982
[TBL] [Abstract][Full Text] [Related]
36. Human epidermal growth factor receptor 2 expressions and Janus-activated kinase/signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway may be associated with clinicopathological features and prognosis of gastric cancer.
Xu W; Fu J; Wu H; Sun W
J Cancer Res Ther; 2018 Jun; 14(Supplement):S311-S318. PubMed ID: 29970682
[TBL] [Abstract][Full Text] [Related]
37. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
38. The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.
Handle F; Puhr M; Schaefer G; Lorito N; Hoefer J; Gruber M; Guggenberger F; Santer FR; Marques RB; van Weerden WM; Claessens F; Erb HHH; Culig Z
Mol Cancer Ther; 2018 Dec; 17(12):2722-2731. PubMed ID: 30254184
[TBL] [Abstract][Full Text] [Related]
39. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
